Island Pharmaceuticals Limited (ASX:ILA)
Australia · Delayed Price · Currency is AUD 0.1900
+0.0200 (11.76%)
Aug 1, 2025, 4:10 PM AEST
Island Pharmaceuticals Company Description
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America.
Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases.
The company has a collaboration agreement with Monash University and National Cancer Institute IND. It also has a cooperative research and development agreement with the U.S. Army, Island in preparation for its Phase 2a/b clinical study for ISLA-101.
Island Pharmaceuticals Limited was founded in 2017 and is based in Camberwell, Australia.
Island Pharmaceuticals Limited
| Country | Australia |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | David Foster |
Contact Details
Address: 697 Burke Road Camberwell, 3124 Australia | |
| Phone | 61 3 7036 7675 |
| Website | islandpharmaceuticals.com |
Stock Details
| Ticker Symbol | ILA |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000138869 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D. | MD, Chief Executive Officer, President and Executive Director |
| Cameron Peter Jones C.A. | Chief Financial Officer and Company Secretary |